Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.
The acquisition brings closure for Mirati at last, though some investors will feel disappointed.
But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.
Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.
But Repare and Black Diamond still have rebuilding to do.